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Insulin Enhances Nitric Oxide Production in Trabecular 
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Purpose:  To investigate the effect of insulin on the production of nitric oxide (NO) in the trabecular 
meshwork (TM) cells and the enzymatic synthetic pathway of tetrahydrobiopterin (BH4) synthesis. 
Methods: Primarily cultured human TM cells were exposed to 1, 10, and 100 µg/ml of insulin and 0, 1, 10, 
100 and 1000 nM dexamethasone for 3 days. To evaluate the enzymatic pathway of BH4 synthesis, 10 µM 
dexamethasone, 5 mM diaminopyrimidinone, 100 µM ascorbic acid, 100 µM sepiapterin, or 10 µM 
methotrexate were also co-administered respectively. Cellular survival and NO production were measured 
with MTT and Griess assay.
Results: Insulin enhanced NO production in a dose-dependent manner significantly (p<0.05) without 
affecting cell viability, whereas dexamethasone inhibited NO production. With co-exposure of insulin, 
diaminopyrimidinone and sepiapterin inhibited insulin-induced NO production. Ascorbic acid increased 
NO production independent of insulin and methotrexate did not affect to the action of insulin in NO 
production. 
Conclusions: Insulin increases NO production in TM cells via de novo synthetic pathway for BH4 synthesis. 
Insulin could be involved in the regulation of trabecular outflow by enhancing NO production in TM cells.
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Nitric oxide (NO) is a short-lived free radical, generated 
from L-arginine by NO synthase (NOS) in an enzymatic 
reaction. It is diffusible across the biological membrane and 
has such diverse roles as an endothelium derived relaxing 
factor, a neuromodulator, and an immunological mediator in 
the cardiovascular, nervous, and immune systems.
1,2 In the 
eye, NO is a physiological regulator as well as a pathological 
mediator not only in the vascular system but also in other 
tissues including the retina and the ocular surface.
3
It has been proposed that the pathogenesis of primary 
open-angle glaucoma may be related to the alteration in the 
trabecular meshwork (TM), the ocular tissue believed to be 
responsible for the majority of aqueous humor outflow 
resistance. TM cells perform a variety of activities in 
maintaining the normal function of the aqueous outflow 
pathway.
The activity of nitric oxide synthase has been shown in the 
TM of bovine, porcine and human eyes.
4-6 Since TM possess 
a contractile properties and the main isoform of NOS in the 
ocular outflow pathway is known to an eNOS,
4 NO can 
affect outflow facility by relaxation of TM. It is also known 
that NO is involved in the regulation of trabecular outflow 
and external administration of NO results in decreased IOP.
7,8 
Alteration of NOS activity is reported in the glaucomatous 
eyes
9 and basal NO production is enhanced by hydraulic 
pressure in cultured human TM cells.
10
Endothelial dysfunction is characterized by an inability of 
endothelial cells to produce adequate amount of bioactive NO 
and hyperglycemia contributes to endothelial dysfunction and 
decreased NO bioavailability
11,12 but the mechanisms remain 
uncharacterized. It has been proposed that high glucose 
inhibits basal eNOS expression, activity, and NO production 
in cultured endothelial cells.
13,14 Insulin is a direct-acting 
vasodilator in intact vessels and has been demonstrated to 
stimulate NO production in cultured endothelial cells.
15-17
Taken together, there is a possibility that insulin can affect 
on the formation of NO in TM cells. The present study was 
designed to investigate whether insulin affect NO production 
in human TM cells. Additionally the enzymatic synthetic 
pathway for tetrahydrobiopterin (BH4) synthesis, an essential 
cofactor for NO synthesis, was also evaluated.Kor J Ophthalmol Vol.21, No.1, 2007
40
Materials and Methods
Cell culture
TM cell cultures were established from enucleated human 
eyes obtained from an eye bank and transported on ice within 
2 hr after exsanguinations as previously described.
18,19 
Briefly, TM tissues were excised by dissecting a continuous 
strand of tissue between the line of Schwalbe and the scleral 
spur, using a curette to separate a continuous strand of TM 
tissue away from the scleral spur, ciliary muscle and 
Schwalbe's line. The excised TM tissues were placed in the 
sterile laminin-coated culture dish with DMEM medium 
containing 15% fetal bovine serum, 2 mM glutamine, 50 
µg/ml gentamicin and 2.5 mg/ml fungizone and left 
undisturbed for 3 to 5 days in a 37℃ incubator with a 5% 
CO2 atmosphere. After identifying initial cell growth, the 
explants were removed and the cultures were maintained with 
a medium containing 10% fetal bovine serum. Passages three 
through five were used for experiments.
Experimental treatment 
With approaching confluency, the cultures were trypsinized 
and inoculated into 24 well culture plates (1×10
6 cells/well). 
After allowing 24 hours for attachment, 1, 10, 100, and 1000 
nM of dexamethasone (Sigma, St. Louis, MO, USA) and 1, 
10, and 100 µg/ml of insulin (Sigma, St. Louis, MO, USA) 
were added to the media with or without NOS inhibitor, 0.5 
mM N
ω-Nitro-L-arginine methyl ester (L-NAME: Sigma, St. 
Louis, MO, USA). In addition, 10 µM dexamethasone, 5 mM 
diaminopyrimidinone, 100 µM L-ascorbic acid, 100 µM 
sepiapterin, or 10 µM methotrexate were added to the medium 
respectively with co-exposure of insulin to evaluate enzymatic 
synthetic pathway of BH4 synthesis. The cultures were 
replaced to the incubator and incubated for 72 hours.
Cell viability
Cell viability was determined by a rapid colorimetric assay 
using 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide (MTT: Sigma, St Louis, MO, USA). The MTT assay 
is based on the ability of the tetrazolium salt MTT to detect 
living but not dead cells. The signal generated, optical 
density (OD) is directly proportional to the number of 
cells.
20,21 After adding 100 µl of an MTT stock solution (5 
mg MTT/ml PBS) to each well, the media was completely 
removed from the well after a 4-hr incubation at 37℃. Then 
0.5 ml of dimethyl sulfoxide (DMSO: Sigma, St Louis, MO, 
USA) was added to each well and 100 µl of the solution from 
each well was transferred to a 96-well plate and read at 570 
nm on a multi-well scanning spectrophotometer. It was noted 
that a minimum 10 min exposure to DMSO was required to 
dissolve the MTT formazan crystals after which the 
absorbance remained constant for 20 min. Thus, in all 
experiments spectrophotometric readings were taken 15 min 
after the addition of DMSO.
Measurement of NO production
Nitrite's concentrations in the media were measured by 
Griess reaction.
22 Briefly, media samples were collected from 
each wells following appropriate treatment and reacted with 
modified Griess reagent (Sigma, St Louis, MO, USA) by 
mixing equal volumes with each other at room temperature 
for 15 min. Optical density was then measured and read on 
a multi-well scanning spectrophotometer at 540 nm. The 
nitrite concentration was then determined from a comparison 
of absorbance with that of a standard solution of sodium 
nitrite in medium. The background absorbance measured 
using the medium alone, was subtracted from all values.
Statistical analysis
Data are expressed as mean±standard error of the mean 
(mean±SEM) corresponding to the number of wells analyzed. 
Experimental differences between control culture results and 
a single treatment group were evaluated using Student's t-test 
with  P values less than 0.05 considered significant.
Results
Cell culture 
The cultured human TM cells were similar in appearance 
to those human TM cells generated by other investigator and 
identification of TM cells was done by their characteristic 
morphology and growth pattern.
18,19 Confluent cultures of 
TM cells grew as a monolayer of closely packed cells with 
branching cell bodies making multiple contacts between cells. 
The cells were flattened with rounded to moderately 
elongated bodies with each cell containing a centrally placed 
nucleus. Often the migrating TM cells showed ruffled borders 
as they detached from the main cell mass. Occasionally 
migrating cells formed satellite colonies of cells with 
identical morphology to the main cell mass.
18,19 This cellular 
morphology was maintained at least for 5 passages.
Effect on cell viability 
Insulin and dexamethsone did not affect significantly on 
the survival of cultured trabecular meshwork cells up to 100 
µg/ml and 1000 nM respectively. Other co-exposed chemical 
agents also did not affect cellular survival (data not shown). 
Thus the effect on NO production of the each chemical agent 
used at experiments does not influenced by cell numbers 
significantly.
Effect on NO productionJW Kim, et al. INSULIN ENHANCES NO IN T CELL
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Fig. 1. Effect of dexamethasone on the production of nitric 
oxide in cultured trabecular meshwork cell exposed for 3 days. 
Dexamethasone decreased nitric oxide production. (*; p<0.05)
Fig. 2. Effect of insulin on the production of nitric oxide on 
cultured human trabecular meshwork cells. Insulin increased 
nitric oxide production in a dose-dependent manner and 
inhibited by 0.5 mM L-NAME (N
ω-Nitro-L-arginine methyl 
ester). (*; p<0.05)
Fig. 3. Effect of 10 µM dexamethasone on the production of 
nitric oxide after co-exposure to insulin. Dexamethasone did not 
affect insulin-induced production of nitric oxide significantly.
(*; p<0.05)
Fig. 4. Effect of 5 mM diaminopyrimidinone on the production
of nitric oxide after co-exposure to insulin. 
Diaminopyrimidionone abolished insulin-induced production of 
nitric oxide. (p>0.05 at each group)
Fig. 5. Effect of 100 µM sepiapterin on the production of nitric
oxide after co-exposure to insulin. Sepiapterin abolished insulin- 
induced production of nitric oxide. (p>0.05 at each group)
Fig. 6. Effect of 100 µM Lascorbic on the production of nitric
oxide after co-exposure to insulin. L-ascorbic acid increased 
nitric oxide production and abolished insulin-induced production 
of nitric oxide. (p>0.05 at each group)
The synthetic glucocorticoid dexamethasone inhibited NO 
production significantly in a dose-dependent manner. Nitrite 
concentration was decreased from 1.60 µM of non-exposed 
control down to 0.89 µM of 1000 nM dexamethasone 
exposure (Fig. 1). On the contrary, insulin enhanced NO 
production significantly in a dose-dependent manner up to 
2.76 µM (Fig. 2). This insulin-induced enhanced NO 
production was inhibited by L-NAME, indicating NO was 
produced by TM cells per se. With co-exposure of insulin, 
10 µM dexamethasone did not affect to the insulin-induced 
increase of NO production (Fig. 3).
Co-exposure of 5 mM diaminopyrimidinone and 100 µM 
sepiapterin, inhibitors of de novo synthetic pathway for BH4 
synthesis, inhibited the insulin-induced increase of NO 
production (Fig. 4, 5). But co-exposure of 100 µM L-ascorbic 
acid, a stimulator of de novo synthetic pathway for BH4 Kor J Ophthalmol Vol.21, No.1, 2007
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Fig. 7. Effect of 100 µM methotrexate on the production of 
nitric oxide after co-exposure to insulin. Methotrexate did not 
affect insulin-induced production of nitric oxide significantly. (*;
p<0.05)
synthesis, increased NO production independent of the 
co-exposure of insulin (Fig. 6). Compared to single exposure 
of 0, 1, 10, and 100 µg/ml, co-exposure of 100 µM L-ascorbic 
further increased NO production 84%, 109.1%, 92.6%, and 
103.3% respectively. Co-exposure of 10 µM methotreaxate, 
an inhibitor of salvage pathway for BH4 synthesis, decreased 
overall NO production but did not affect to the insulin- 
induced increase of NO production (Fig. 7). Compared to 
single exposure of 0, 1, 10, and 100 µg/ml, co-exposure of 
10 µM methotrexate further decreased NO production 56.9%, 
54.6%, 77.8%, and 70.9% respectively. These findings suggest 
that insulin increases NO production via enhancing de novo 
synthetic pathway for BH4 synthesis in cultured TM cells.
Discussion
The main findings of this study are 1) dexamethasone 
inhibited NO production; 2) insulin enhanced NO production; 
and 3) enzymatic pathway of insulin-induced enhanced NO 
production is via stimulating de novo synthetic pathway for 
BH4 synthesis.
Since TM cells possess endothelial-like, smooth muscle 
cell-like activities, and NOS activities are expressed trabecular 
outflow pathway,
4 NO could affect on the outflow facility 
by regulating the contractility TM. The concentration of 
endothelin, one of the most potent vasoconstrictors, which 
counteracts with NO,
23 is increased in patients with 
progressive open angle glaucoma.
24 In addition, NO possesses 
antiplatelet aggregatory activity and decreases leukocyte 
adhesion.
1,3 Several studies have shown that NO is involved 
in the regulation of intraocular pressure and suggest that NO 
could increase the trabecular outflow by its innate dilating 
activity, thus result in the relaxation of TM and decrease of 
intraocular pressure. Recent findings have demonstrated that 
NO can serve as an ocular hypotensive agent.
7,25-29 The 
NO/guanylate cyclase system plays a role in aqueous humor 
dynamics and in the regulation of intraocular pressure.
30
In endothelial cells, high glucose inhibits NO production 
and result in oxidative stress subsequently.
11-13 In the present 
study, a synthetic glucocorticoid dexamethasone decreased 
NO production in a dose-dependent manner in TM cells. 
Activity of eNOS can be modified in disease states, and in 
diabetes hyperglycemia inhibits eNOS as a result of a 
posttranslational modification at the protein kinase Akt 
regulatory site.
14 Clinically such inhibition of NO production 
by glucose may be associated with increased intraocular 
pressure in steroid-induced glaucoma or diabetes (the 
concentration of glucose in the aqueous humor is higher in 
diabetes).
31 Endothelin-1 expression was also induced by 
glucose
32 and was increased in diabetes.
33 On the contrary, 
insulin promotes vasodilatation by enhancing NO production 
in endothelial cells.
15-17 As in the endothelial cells, insulin 
also increased NO production in TM cells in a dose- 
dependent manner in the present study, suggesting the 
beneficial effect of insulin on the regulation of trabecular 
outflow by relaxation activity of NO in TM.
The gasotransmitter NO is synthesized by oxidation of 
L-arginine and many cofactors are involved in the synthesis 
of NO. Among them, the pteridine cofactor BH4 has emerged 
as a critical determinant of NOS activity.
34 BH4 is an 
essential cofactor for the proper flow of electrons to oxidize 
L-arginine, and NOS is the only heme-containing enzyme 
known to require a pterin cofactor for activity. Of significant 
interest, therefore, is that a reduced availability of BH4 may 
be a key factor in the etiology of the endothelial dysfunction. 
BH4 synthesis occurs via two distinct pathways: a de novo 
synthetic pathway which uses GTP as a precursor and a 
salvage pathway for preexisting dihydropterins.
35 To evaluate 
the enzymatic synthetic pathway for BH4 synthesis involved 
in the insulin-induced enhanced NO production in TM cells, 
several inhibitors and stimulators of BH4 synthesis were 
tested in this study. Insulin's enhancing action on the NO 
production did not affected by dexamethsone, a known 
inhibitor of de novo synthetic pathway for BH4 synthesis. 
This finding suggests insulin could overwhelm the inhibitory 
action of dexamethasone on the NO production. However 
insulin's enhancing action on the NO production was 
markedly abolished by diaminopyrimidinone, another known 
inhibitor of de novo synthetic pathway for BH4 synthesis. 
Sepiapterin, acts as an inhibitor of de novo synthetic pathway 
for BH4 synthesis if not stimulated, also abolished insulin's 
enhancing action on the NO production.
Recently, several studies have shown that ascorbic acid, a 
stimulator of de novo synthetic pathway for BH4 synthesis, 
potentiates endothelial NO synthesis in a dose-time-dependent 
fashion
36 and may protect NO from inactivation via chemical 
stabilization of BH4 in endothelial cells.
37,38 Although 
ascorbic acid increased NO synthesis in this study, it 
abolished insulin's enhancing action on the NO production. 
Furthermore methotrexate, an inhibitor of salvage pathway 
for BH4 synthesis, markedly inhibited NO production despite 
of insulin's enhancing action on the NO production. These 
findings suggest that insulin enhances NO production in 
cultured human TM cells via de novo pathway of BH4 JW Kim, et al. INSULIN ENHANCES NO IN T CELL
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synthesis and ovewhelms the inhibitory action of glucocorticoid 
on the BH4-dependent endothelial function.
Preservation of the bioavailability of NO should be 
considered significant in the TM since NO is known to a 
cellular mediator that can modulate vascular tone as well as 
aqueous humor dynamic in the eye.
39 Beside from its role in 
the regulation of trabecular outflow, another possible roles of 
NO also could be considered. The tissues facing the anterior 
chamber of the eye are exposed constantly to aqueous 
containing reactive oxygen products generated by light- 
catalyzed reactions. Such radicals may cause increased 
oxidation in tissues of the anterior eye segment and finally 
lead to oxidative damage. Oxidative stress that exceeds the 
capacity of the TM for detoxification could result in damage 
of TM cells and subsequent alteration of aqueous outflow 
resistance. Oxidative stress induces unavailability of BH4 and 
causes NOS to generate reactive oxygen substances. This will 
result both in NO depletion, and in peroxynitrite-dependent 
oxidation of BH4. Probably the resultant oxidative stress 
causes TM cell damage. Previous studies demonstrated 
decreased antioxidant potential of aqueous humor
40,41 and 
increased oxidative DNA damage in the glaucomatous 
eyes.
42,43 Chronic oxidative stress-induced TM cell damage 
has been suggested as an another possible pathogenetic 
mechanism of glaucoma recently.
44
Recent report demonstrated the increased cellular senescence 
in the outflow pathway of glaucomatous eyes.
45,46 Chronic 
oxidative stress, which resulted from NO dysregulation, also 
can provoke cellular senescence including TM cells.
47,48 High 
glucose is known to cause cellular senescence and NO can 
delay cellular senescence caused by chronic oxidative 
stress.
49,50 Thus the possible significance of preserving the 
bioavailability of NO in TM includes not only maintain 
trabecular outflow but also decrease oxidative stress, hence 
delay cellular senescence. Additional studies should focus on 
determining the most effective therapeutic approach for 
preventing oxidative stress and reducing the development 
and/or progression of glaucomatous optic neuropathy.
In summary, NO could decrease chronic oxidative stress 
of TM and delay aging of TM cells. This study suggests that 
insulin might play for a role in the maintenance of TM 
function by enhancing NO production via de novo pathway 
of BH4 synthesis. Further studies will be required to ascertain 
such roles of NO in TM. 
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